恩度联合化疗对中晚期非小细胞肺癌患者PFS及OS的影响  

Effect of endostar combined with chemotherapy on PFS and OS in patients with middle-advanced non-small cell lung cancer

作　　者：徐晓暇 XU Xiaoxia(Shangrao Fifth People's Hospital,Shangrao 334000,China)

机构地区：[1]上饶市第五人民医院肿瘤一科

出　　处：《国外医学（医学地理分册）》2019年第4期407-409,共3页Foreign Medical Sciences：Section of Medgeography

摘　　要：目的探讨恩度联合化疗对中晚期非小细胞肺癌(NSCLC)患者无进展生存期(PFS)及总生存期(OS)的影响。方法选取2017年3月—2019年3月本院收治的确诊为中晚期NSCLC患者65例。随机分为2组,对照组32例,观察组33例。对照组采用单纯化疗治疗,观察组采用恩度联合化疗治疗。对比两组临床疗效、疾病无进展生存期(PFS)和总生存期(OS)以及血清肿瘤标志物水平。结果治疗3个疗程,观察组临床有效率略高于对照组,但差异无统计学意义(P>0.05);观察组PFS、OS时间长于对照组,差异有统计学意义(P<0.05);观察组癌胚抗原(CEA)、糖抗原(CA125)、细胞角蛋白19片段抗原(CYFRA21-1)水平均低于对照组,差异有统计学意义(P<0.05)。结论恩度联合化疗治疗中晚期NSCLC效果确切,可有效降低肿瘤标志物水平,消除病症,从而延长患者生存周期,具有较高临床应用价值。Objective To investigate the effect of endostar combined with chemotherapy on progression free survival(PFS)and overall survival(OS)in patients with middle-advanced non-small cell lung cancer(NSCLC).Methods 65 patients with middle-advanced NSCLC in the hospital from March 2017 to March 2019 were randomly divided into control group(32 cases)and observation group(33 cases).control group was given chemotherapy,and observation group was given endostar combined with chemotherapy.The clinical efficacy,PFS,OS,serum tumor markers were compared between two groups.Results After treatment for 3 courses,the clinical effective rate of observation group was slightly higher than that of control group,but the difference was not statistically significant(P>0.05);The PFS and OS of observation group were longer than those of control group(P<0.05);The levels of carcinoembryonic antigen(CEA),carbohydrate antigen(CA125)and cytokeratin 19-fragment antigen(CYFRA21-1)in observation group were lower than those in control group(P<0.05).Conclusion Endostar combined with chemotherapy in treatment middle-advanced NSCLC is effective,it can decrease the levels of tumor markers and prolong survival time,which has higher clinical application value.

关 键 词：非小细胞肺癌 恩度 化疗 无进展生存期 总生存期 

分 类 号：R735[医药卫生—肿瘤]